CELC
Celcuity Inc.
NASDAQ · USHealthcareBiotechnology
$87.99-0.44%
Price as of Jul 20, 2026
CELC financials
Celcuity Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $167.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | -$167.0K | $0.00 | $0.00 | $0.00 |
| Operating expenses | $172.2M | $113.3M | $66.2M | $39.4M |
| Operating income | -$172.2M | -$113.3M | -$66.2M | -$39.4M |
| Net income | -$177.0M | -$111.8M | -$63.8M | -$40.4M |
| EBITDA | -$159.7M | -$101.4M | -$58.3M | -$38.1M |
| Basic EPS | $-3.78 | $-2.83 | $-2.69 | $-2.68 |
| Diluted EPS | $-3.78 | $-2.83 | $-2.69 | $-2.68 |
| Balance sheet | ||||
| Cash & equivalents | $165.7M | $22.5M | $30.7M | $24.6M |
| Total assets | $466.6M | $245.1M | $191.2M | $175.7M |
| Total liabilities | $366.0M | $129.5M | $51.5M | $41.9M |
| Stockholders’ equity | $100.6M | $115.6M | $139.8M | $133.8M |
| Total debt | $195.4M | $98.0M | $37.4M | $35.2M |
| Net debt | $29.7M | $75.4M | $6.8M | $10.7M |
| Cash flow | ||||
| Operating cash flow | -$153.3M | -$83.5M | -$53.8M | -$36.0M |
| Capital expenditure | -$249.0K | -$249.9K | -$97.6K | -$158.8K |
| Free cash flow | -$153.5M | -$83.7M | -$53.9M | -$36.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |